Product Pipeline
Clinical-Stage Products Focused on Novel Targets
Oncternal Therapeutics is a clinical-stage oncology company developing potentially first-in-class, novel therapies that target a broad spectrum of cancers with large unmet medical need. By leveraging pathways absent or minimally expressed in normal cells or tissue, we aim to impact cancer cell growth while reducing potential harm to healthy cells. We continue to investigate the potential to treat additional malignancies with our product candidates and intend to broaden the indications we are studying.
We are enrolling patients:
With Relapsed or Refractory B-Cell Malignancies for a Phase 1/2 study of ONCT-808, our ROR1-Targeting Autologous Cell Therapy (NCT05588440)